Cullinan Oncology, Inc. (CGEM) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow on course for slim gains at open as Iran tensions clash with AI optimism
- Oil retreats from one-month high as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Cullinan Oncology Inc. (CGEM) PT Lowered to $38 at Morgan Stanley
August 8, 2024 11:56 AM EDTMorgan Stanley analyst Jeffrey Hung lowered the price target on Cullinan Oncology Inc. (NASDAQ: CGEM) to $38.00 (from $40.00) while maintaining a Overweight rating.
The analyst comments "With earnings, Cullinan reported multiple updates across its portfolio. The biggest update is that the company will pursue rheumatoid arthritis (RA) as... More
